Biogen Inc. (BIIB) Q1 2026 (USD): Adj. EPS 3.57 (exp. 2.99), Revenue 2.5bln (exp. 2.25bln); sees FY Adj. EPS 14.20-15.25 (exp. 15.46, prev. saw 15.25-16.25)

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

Humana Inc. (HUM) Q1 2026 (USD): EPS 10.31 (exp. 10.21), Revenue -- (exp. 39.37bln); revises GAAP FY EPS guidance to "at least" 8.36 (prev. "at least" 8.89), affirms Adj. EPS guidance of "at least 9.00"

BoE PRA publishes plans to support resilience in the life insurance industry

Biogen Inc. (BIIB) Q1 2026 (USD): Adj. EPS 3.57 (exp. 2.99), Revenue 2.5bln (exp. 2.25bln); sees FY Adj. EPS 14.20-15.25 (exp. 15.46, prev. saw 15.25-16.25)

Newsquawk Daily US Opening News - 29th April 2026

German Chancellor Merz says that his personal relationship with US President Trump continues to remain "good"

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.
  • Updated guidance includes an approximately USD 1.00 impact from acquired IPR&D charges resulting from ongoing business development activities to support Biogen's growth strategy

Context

Biogen Inc. reported a strong Q1 2026, beating both EPS and revenue expectations significantly. However, their FY guidance was slightly reduced, with IPR&D charges impacting adjusted earnings, which investors may view as a mixed signal regarding future profitability and growth strategies in an already competitive biotech sector.

Related headlines

The feed had this first.

Use the Platform